Phase 2 Trial of Bright White Light Therapy to Reduce Fatigue and Depression in Men 60 and Older With Advanced Prostate Cancer Receiving ADT Combination Treatment

What this Trial Is About

Researchers are evaluating how bright white light BWL therapy may help reduce cancer-related fatigue and depression in men with advanced prostate cancer undergoing antiandrogen therapy ADT combination treatments. This phase II trial focuses on patients whose cancer has spread locally or to distant parts of the body. Since ADT combination therapy lowers testosterone to slow tumor growth but can worsen fatigue and depression, BWL therapy aims to support circadian rhythms and mood during treatment. Participants are randomly assigned to one of two groups. One group starts wearing AYOpro bright white light therapy glasses immediately on day 1 of their ADT combination therapy for 12 months. The other group begins the same BWL therapy 6 months after starting ADT combination therapy and continues for 6 months. The ADT combination treatment includes ADT with chemotherapy and androgen receptor targeted therapy or ADT with androgen receptor targeted therapies alone. During the 52-week study, participants will complete questionnaires assessing fatigue, mood, geriatric health, and overall quality of life. Researchers will monitor patient-reported fatigue changes after 3 months of treatment as the primary outcome. Secondary outcomes include mood, geriatric assessments, and quality of life changes over the same period. Safety and treatment adherence will be tracked throughout, with follow-up continuing for 4 weeks after stopping therapy or until death.

Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy